Serelaxin
Sponsors
Corthera, Inc.(formerly BAS Medical, Inc.), a member of the Novartis group of companies, Novartis Pharmaceuticals, University of Edinburgh
Conditions
Acute Heart FailureAcute Heart Failure (AHF)Chronic Heart FailureCoronary Artery DiseaseEnd-Stage Renal DiseaseHypertension, PortalLabor, InducedLiver Cirrhosis
Phase 1
Phase 2
Recombinant Human Relaxin (rhRlx) in Pregnant Women Scheduled for Induction of Labor
CompletedNCT00259103
Start: 2005-11-30End: 2006-10-31Updated: 2014-05-07
Study of the Vascular Effects of Serelaxin
CompletedNCT01979614
Start: 2014-02-03End: 2016-08-17Updated: 2019-07-01
Study of Safety, Tolerability and Pharmacokinetics of Serelaxin in Japanese Acute Heart Failure (AHF) Patients
CompletedNCT02002702
Start: 2014-01-31End: 2014-08-31Updated: 2015-10-12
Pharmacokinetics & Safety of Serelaxin on Top of Standard of Care Therapy in Pediatric Patients With Acute Heart Failure
TerminatedNCT02151383
Start: 2014-09-05End: 2017-04-03Updated: 2019-06-25
Study of the Effect of Serelaxin on High-sensitivity Cardiac Troponin I (Hs-cTnI) Release in Patients With Chronic Heart Failure
TerminatedNCT02625922
Start: 2016-02-05End: 2017-01-11Updated: 2018-09-21
Serelaxin To Lower Portal Pressure
CompletedNCT02669875
Start: 2017-10-18End: 2018-08-31Updated: 2018-10-11
Phase 3
Efficacy, Safety and Tolerability of Sexelaxin When Added to Standard Therapy in AHF
TerminatedNCT02007720
Start: 2014-03-12End: 2017-06-16Updated: 2019-08-02
Effect of Serelaxin Versus Standard of Care in Acute Heart Failure (AHF) Patients
TerminatedNCT02064868
Start: 2014-01-31End: 2017-04-25Updated: 2019-03-22